drugset / Trial / NCT05561491
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 \[PD-1\] inhibitor).
Timeline
- Start
- 2024-01
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | ONCOS-102 | Unknown | 3e+11 vg | Intrathecal |
| Subject | ONCOS-102 | Unknown | 1e+12 vg | Intrathecal |